TLDRS
- HIMS erased FTC-related losses and rallied nearly 23% from recent lows.
- Investors now focus on whether second-half EBITDA targets are realistically achievable.
- U.S. revenue and gross margin remain the most important earnings indicators.
- Eucalyptus integration and branded weight-loss drugs add execution and margin pressure.
Hims & Hers Health shares staged a powerful rebound ahead of the company’s upcoming earnings report, but the stock’s recovery has shifted investor attention from regulatory fears to a much tougher question, can the company deliver the sharp profitability improvement embedded in its second-half guidance?
The stock closed at $30.82 on Monday, up 10.98%, and added modestly in after-hours trading. The rally not only outperformed the broader market, it also pushed shares above the level seen before the Federal Trade Commission lawsuit that triggered a steep selloff in late July.
From the lawsuit-day low of $25.00, HIMS has surged roughly 23%, effectively erasing the regulatory damage in less than a week. The speed of the recovery suggests investors are looking beyond the legal headline and refocusing on the company’s growth trajectory, especially in weight-loss treatments and international expansion.
Hims & Hers Health, Inc., HIMS
Rally Erases Regulatory Damage
The rebound marks a dramatic reversal from last week’s turbulence. Shares had plunged nearly 15% after the FTC alleged violations involving privacy, billing and cancellation practices. Hims & Hers has rejected the allegations and said it intends to defend itself vigorously.
While the legal case remains unresolved, the market’s immediate concern has clearly shifted. Traders are now positioning for the company’s second-quarter earnings report scheduled for August 10, with options markets implying a move of about 14% in either direction.
That implied swing is slightly below the average expected move seen before the company’s previous eight earnings releases, indicating investors still anticipate significant volatility but not an unusually extreme reaction.
Guidance Puts Margins In Focus
The bigger issue lies inside management’s financial outlook. Based on the midpoint of the company’s May guidance, second-quarter revenue is expected to rise to around $690 million, up about 13.5% from the first quarter.
However, adjusted EBITDA is projected to increase only marginally, implying a quarterly margin of roughly 6.5%, down from 7.3% in Q1.
The real scrutiny begins when investors look at what is required for the full year. To reach the midpoint of management’s annual target, Hims would need to generate approximately $223 million in adjusted EBITDA during the second half of 2026, compared with an estimated $89 million in the first half.
That implies a second-half EBITDA margin of nearly 13.9%, more than double the level implied for the first half.
Such a steep improvement is not impossible, but it represents a substantial acceleration in profitability over a very short period.
Weight-Loss Strategy Under Pressure
The margin challenge is closely tied to the company’s evolving product mix.
Hims has increasingly focused on branded weight-loss medications, including Novo Nordisk’s Wegovy and Ozempic. Those products can support strong revenue growth, but they also carry higher costs than some of the company’s earlier offerings.
First-quarter results already reflected that pressure. Revenue grew modestly, but gross margin fell from 73% to 65%, and adjusted EBITDA dropped by more than half year over year.
The company also saw a decline in U.S. revenue, while international revenue surged from a much smaller base. Subscriber growth remained positive, but monthly revenue per subscriber moved lower, adding another layer of pressure to margins.
Eucalyptus Integration Raises Stakes
Another important variable is the acquisition of Eucalyptus, which Hims completed in June.
The deal expands the company’s footprint across Australia, Canada, Germany, Japan and the United Kingdom and adds a business that had served more than 850,000 customers before the acquisition.
Because Eucalyptus was not included in the original May guidance, investors are trying to determine how it will affect both revenue growth and profitability. Integration costs could weigh on near-term margins, while scale benefits may take longer to emerge.
Management has previously said growth should accelerate during the remainder of the year. Analysts now want evidence that the company’s earnings power has stabilized and can begin expanding again.
That makes the upcoming report less about whether Hims is growing and more about how efficiently it can grow.
The stock has already recovered from the regulatory shock. The next test is whether the company can convince investors that its ambitious second-half EBITDA targets are achievable without sacrificing the growth story that fueled the rebound.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
